{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:32:54Z","timestamp":1787020374665,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04385-4","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T13:17:38Z","timestamp":1759756658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy, safety, and exploratory biomarker analysis of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: a prospective, single-arm, phase II trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiao","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lupeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanli","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunchang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"issue":"3","key":"4385_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"Pt 2","key":"4385_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.semcancer.2022.03.006","volume":"86","author":"X Yin","year":"2022","unstructured":"Yin X, Li Y, Wang H, Jia T, Wang E, Luo Y, et al. Small cell lung cancer transformation: From pathogenesis to treatment. Semin Cancer Biol. 2022;86(Pt 2):595\u2013606.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"4385_CR3","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","volume":"39","author":"JM Chan","year":"2021","unstructured":"Chan JM, Quintanal-Villalonga \u00c1, Gao VR, Xie Y, Allaj V, Chaudhary O, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021;39(11):1479-96.e18.","journal-title":"Cancer Cell"},{"issue":"8","key":"4385_CR4","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.mayocp.2019.01.034","volume":"94","author":"S Wang","year":"2019","unstructured":"Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc. 2019;94(8):1599\u2013622.","journal-title":"Mayo Clin Proc"},{"key":"4385_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040820","author":"MG Raso","year":"2021","unstructured":"Raso MG, Bota-Rabassedas N, Wistuba II. Pathology and classification of SCLC. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13040820.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"4385_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.21.01881","volume":"40","author":"J Zugazagoitia","year":"2022","unstructured":"Zugazagoitia J, Paz-Ares L. Extensive-stage small-cell lung cancer: first-line and second-line treatment options. J Clin Oncol. 2022;40(6):671\u201380.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4385_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrclinonc.2017.71","volume":"14","author":"JK Sabari","year":"2017","unstructured":"Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549\u201361.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"4385_CR8","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.jtho.2021.07.018","volume":"16","author":"BH Herzog","year":"2021","unstructured":"Herzog BH, Devarakonda S, Govindan R. Overcoming chemotherapy resistance in SCLC. J Thorac Oncol. 2021;16(12):2002\u201315.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4385_CR9","first-page":"39","volume":"5","author":"F Koinis","year":"2016","unstructured":"Koinis F, Kotsakis A, Georgoulias V. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res. 2016;5(1):39\u201350.","journal-title":"Transl Lung Cancer Res"},{"key":"4385_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"4385_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","volume":"13","author":"Q Tang","year":"2022","unstructured":"Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, et al. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442.","journal-title":"Front Immunol"},{"issue":"11","key":"4385_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","volume":"11","author":"Q Gou","year":"2020","unstructured":"Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q, et al. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020;11(11):955.","journal-title":"Cell Death Dis"},{"issue":"8","key":"4385_CR13","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1158\/2159-8290.CD-20-0913","volume":"11","author":"NR Mahadevan","year":"2021","unstructured":"Mahadevan NR, Knelson EH, Wolff JO, Vajdi A, Saig\u00ed M, Campisi M, et al. Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity. Cancer Discov. 2021;11(8):1952\u201369.","journal-title":"Cancer Discov"},{"issue":"3","key":"4385_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346-60.e7.","journal-title":"Cancer Cell"},{"issue":"23","key":"4385_CR15","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u20139.","journal-title":"N Engl J Med"},{"issue":"10212","key":"4385_CR16","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929\u201339.","journal-title":"Lancet"},{"key":"4385_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109275","volume":"132","author":"H Park","year":"2020","unstructured":"Park H, Hatabu H, Ricciuti B, Aijazi SJ, Awad MM, Nishino M. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. Eur J Radiol. 2020;132:109275.","journal-title":"Eur J Radiol"},{"issue":"5","key":"4385_CR18","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00262-021-03052-w","volume":"71","author":"S Lee","year":"2022","unstructured":"Lee S, Shim HS, Ahn BC, Lim SM, Kim HR, Cho BC, et al. Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. Cancer Immunol Immunother. 2022;71(5):1093\u2013101.","journal-title":"Cancer Immunol Immunother"},{"key":"4385_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.604227","volume":"11","author":"W Hou","year":"2021","unstructured":"Hou W, Zhou X, Yi C, Zhu H. Immune check point inhibitors and immune-related adverse events in small cell lung cancer. Front Oncol. 2021;11:604227.","journal-title":"Front Oncol"},{"issue":"1","key":"4385_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12885-023-10784-8","volume":"23","author":"L Li","year":"2023","unstructured":"Li L, Yang D, Min Y, Liao A, Zhao J, Jiang L, et al. First-line atezolizumab\/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer. BMC Cancer. 2023;23(1):318.","journal-title":"BMC Cancer"},{"issue":"1","key":"4385_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-021-01095-1","volume":"14","author":"J Li","year":"2021","unstructured":"Li J, Deng Y, Zhang W, Zhou AP, Guo W, Yang J, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14(1):95.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"4385_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","volume":"32","author":"B Bittner","year":"2018","unstructured":"Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425\u201340.","journal-title":"BioDrugs"},{"issue":"2","key":"4385_CR23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s12325-021-01996-0","volume":"39","author":"C Jackisch","year":"2022","unstructured":"Jackisch C, Manevy F, Frank S, Roberts N, Shafrin J. White paper on the value of time savings for patients and healthcare providers of breast cancer therapy: the fixed-dose combination of Pertuzumab and Trastuzumab for subcutaneous injection as an example. Adv Ther. 2022;39(2):833\u201344.","journal-title":"Adv Ther"},{"issue":"9","key":"4385_CR24","first-page":"e1514","volume":"26","author":"KP Papadopoulos","year":"2021","unstructured":"Papadopoulos KP, Harb W, Peer CJ, Hua Q, Xu S, Lu H, et al. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody. Patients with Advanced Solid Tumors Oncologist. 2021;26(9):e1514\u201325.","journal-title":"Patients with Advanced Solid Tumors Oncologist"},{"issue":"5","key":"4385_CR25","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10637-022-01287-7","volume":"40","author":"T Shimizu","year":"2022","unstructured":"Shimizu T, Nakajima TE, Yamamoto N, Yonemori K, Koyama T, Kondo S, et al. Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. Invest New Drugs. 2022;40(5):1021\u201331.","journal-title":"Invest New Drugs"},{"issue":"11","key":"4385_CR26","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748\u201356.","journal-title":"J Clin Oncol"},{"issue":"23","key":"4385_CR27","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412\u201320.","journal-title":"Clin Cancer Res"},{"key":"4385_CR28","unstructured":"Therneau T. A package for survival analysis. R package. 2.37\u20132. 2012."},{"issue":"30","key":"4385_CR29","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","volume":"32","author":"P Blanche","year":"2013","unstructured":"Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381\u201397.","journal-title":"Stat Med"},{"issue":"5","key":"4385_CR30","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26(5):688\u201392.","journal-title":"Nat Med"},{"issue":"1","key":"4385_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02252-5","volume":"10","author":"M Xie","year":"2025","unstructured":"Xie M, Bao M, Dong X, Wu L, Liu L, Zhao J, et al. Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study. Signal Transduct Target Ther. 2025;10(1):168.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"4385_CR32","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.ccell.2024.08.013","volume":"42","author":"J Xu","year":"2024","unstructured":"Xu J, Wan R, Cai Y, Cai S, Wu L, Li B, et al. Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer. Cancer Cell. 2024;42(9):1598-613.e4.","journal-title":"Cancer Cell"},{"issue":"6","key":"4385_CR33","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739\u201347.","journal-title":"Lancet Oncol"},{"issue":"12","key":"4385_CR34","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328(12):1223\u201332.","journal-title":"JAMA"},{"key":"4385_CR35","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/celldisc.2017.4","volume":"3","author":"F Zhang","year":"2017","unstructured":"Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 2017;3:17004.","journal-title":"Cell Discov"},{"issue":"10","key":"4385_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e10775","volume":"8","author":"Y Li","year":"2022","unstructured":"Li Y, Zhu X, You J, Zhang B, Huang X, Jin C. Efficacy of bivalent CEACAM6\/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice. Heliyon. 2022;8(10):e10775.","journal-title":"Heliyon"},{"issue":"5","key":"4385_CR37","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s10238-022-00888-z","volume":"23","author":"R Qin","year":"2023","unstructured":"Qin R, Ren W, Ya G, Wang B, He J, Ren S, et al. Role of chemokines in the crosstalk between tumor and tumor-associated macrophages. Clin Exp Med. 2023;23(5):1359\u201373.","journal-title":"Clin Exp Med"},{"key":"4385_CR38","volume":"67","author":"X Pu","year":"2024","unstructured":"Pu X, Lin G, Xiao M, Lin J, Wang Q, Kong Y, et al. Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study. eClin Med. 2024;67:102403.","journal-title":"eClin Med"},{"issue":"2","key":"4385_CR39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/bjc.2015.193","volume":"113","author":"SC Wightman","year":"2015","unstructured":"Wightman SC, Uppal A, Pitroda SP, Ganai S, Burnette B, Stack M, et al. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. Br J Cancer. 2015;113(2):327\u201335.","journal-title":"Br J Cancer"},{"key":"4385_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104738","volume":"211","author":"T Braun","year":"2025","unstructured":"Braun T, Bisht A, Zhu C, Idrees M, Alabeedi F, Kujan O. Diagnostic, prognostic, and metastatic value of chemokines as biomarkers for oral squamous cell carcinoma and their precursor lesions - a systematic review. Crit Rev Oncol Hematol. 2025;211:104738.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"4385_CR41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.immuni.2021.11.002","volume":"55","author":"AJ Ozga","year":"2022","unstructured":"Ozga AJ, Chow MT, Lopes ME, Servis RL, Di Pilato M, Dehio P, et al. CXCL10 chemokine regulates heterogeneity of the CD8(+) T cell response and viral set point during chronic infection. Immunity. 2022;55(1):82-97.e8.","journal-title":"Immunity"},{"issue":"1","key":"4385_CR42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12964-025-02033-1","volume":"23","author":"Y Xia","year":"2025","unstructured":"Xia Y, Huang C, Zhong M, Zhong H, Ruan R, Xiong J, et al. Targeting HGF\/c-MET signaling to regulate the tumor microenvironment: implications for counteracting tumor immune evasion. Cell Commun Signal. 2025;23(1):46.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"4385_CR43","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1186\/s12885-023-10995-z","volume":"23","author":"C Zhao","year":"2023","unstructured":"Zhao C, Tong L, Liu B, Qi F, Zhang Z, Guo Y, et al. Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer. BMC Cancer. 2023;23(1):973.","journal-title":"BMC Cancer"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04385-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04385-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04385-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T13:17:40Z","timestamp":1759756660000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04385-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4385"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04385-4","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was approved by the Ethics Committee of Chinese PLA General Hospital (S2020-466\u201301), and conducted in accordance with the Declaration of Helsinki, good clinical practice (GCP) guidelines, and applicable local regulations. All patients provided consent for data collection and analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"535"}}